.&' () * +,-. /0123 $45 67 &' 892.:# &" :3 B!"# $% : . * *:7 63 $&' EH 6'.

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download ".&' () * +*,-. /0123 $4*5 67 &' 892.:# &" :3 B!"# $% : . * *:7 63 $&' EH 6'."

Μέγαιρα Λαιμός
5 χρόνια πριν
Προβολές:

1 1394/8/30 : 1394/12/9 : 1395 $%&' ( "#/371 / "! 4 :!" "!.&' () * +*,-. /0123 $4*5 67 &' 892.:# &" :3 B!"# $% :.1<+ :3 (:.* &-C 67 &' 63 1D. *:A3 4!<=. *'>+ /0' : &BGH :3 :() *!D? :(:.* 67 (CLH) Cutaneous lymphoid hyperplasia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mg/lesion) # % $/4 Cutaneous lymphoid hyperplasia) "# $% $ &%! (CLH "1- % 2 3% ( - # & #. #/' (0'() *+,- % :( +#;( 91& CLH */4.#6# 6 7 $% 8&.(1) (6# 7 $% =&9<% 9B 8% %?? 6@% "+& 6# H % 2#'= % $/4 EFG-.# & C *6 D 6 2 #. 9B IJK % LM $/4 # 1N%.# & 7.( ( 6# - $/4 "# $% '= +-6 #/' O6;-.(2) 9= J 8+ $% '1 6@% 4 6;Q $% $/R A 6#.## (& 8 6# T@H '6 6# % $ -@'6 U? *6 D $% '= */4 % $= 41!( * + *,-. *,-. % '() & #$ elahe_md2003@yahoo.com * + *,-. *,-. % '() & %! " #$ * + *,-. *,-. % '() & %! " #$ *, *, % '() & 2 1( -1-2! ) #% -3 : 114

2 " # 9,-? = 10 * $ % $ 9 &# # 8 6 G<.(3 "+&) 9& # 6 W? - = A # $ K ( 6# # /' 9 = * / = 9& ( ) $ %? + ; < $ / 6# [ ( Q6 - (# 6@%. & 2 ' =? 60 [G ; < '= % & #6# H ' 6 1( 6 6# 9 & # " # 1N% %.# % &. G( 2 $46 B < G ;6 # B $ 6 % H % % 8 = ' ( 8) 0 )d (6 6#.? + <8 G $. Q = O 6;- Y W ) / 1Z M $'<.# % / 1Z % $ K ( $/ 4 K 76# $ K ( & 'H ) % 8 6# 6. G( 2 # ; ( 6# $ $3% = 6# CD3 # Q2 + CD20 - 'H G 9 = +.(4 "+&) & 2# # E FG- CLH $ 9= & 9<.1 $ % 6 9 B 8 % 6 # /'? $% # % 2 G( 7.( 10 4 $% &!" #.2 ( 6# $( Q a % $XF 6-6#.# $/ 2 & 8 N D (b) "# $%& '(! /371 / 34 % $ = 65!( C 2 ; # K ( 6# ;

" # + -6 % 8 6# 9,- # 1N% $ '< Q 6 W */ 4f 6 A 'H &.

=2# K 9< G $ # % 6# 6 '() /4 '= ;< * / 4 # /- 2 G( "D K (G

= 10 # K 6 @ % $XF 6-6# 6 W ( 6# 9& ( ( 6# @ & +G K "@B

(5 "+&) $ K ( 6# # /' - (#. G( 2 $ - @' 6 U 6 @%.

+ ; < $ / 6# G $( Q *6 D / 1Z ) "@B $% H % 6 @ % M!

(# f N- N [ ( Q6 [G ) %8 # B 8 6# 7 @- 6# 9,- 6 @ % 6# 10

9< $'< 6 ;Q 6 CLH 8) $. '( [' *6 D $% $/ 4.

# % *6 D $ K ( 6 # g6 B " # $ % T @ H ' 6 % 8 6# $H j Z 6

3 " # + -6 % 8 6# 9,- # 1N% $ '< Q 6 W */ 4f 6 A 'H &.# % $'<.# % 2# b +(? =2# K 9< G $ # % 6# 6 '() /4 '= ;< * / 4 # /- 2 G( "D K (G $( Q 9@= $% # % Q6 = 8 Z = "1W? = 10 # K % $XF 6-6# 6 W ( 6# 9& ( ( & +G K "@B 9,- $ 9& # # # % $ '< # 1N% 8 6# e # % $ '< Q.(5 "+&) $ K ( 6# # /' - (#. G( 2 $ 6 U &2 #$ / 6#? + ; < $ / 6# G $( Q *6 D / 1Z ) "@B $% H % % M!.# % / 1Z ; ( #T@ H '6 6 W $ ' 18 A -! N. (# f N- N [ ( Q6 [G ) %8 # B 8 6# 6# 9,- % 6# 10 mg/lesion /% 2 * / 4.9< Q & #6# H ' 6 O 6;- 1( 7 ( #6#.9< $'< 6 ;Q 6 CLH 8) $. '( [' *6 D $% $/ 4.# % O 6;- A K (G B 9& # % $/ 4 " 26 $46 B K % #6# = $. Q = g6 B g6 B A A 'H = 10 4 $% & '() I h % $ # % # % $/ 4 " +, 6# 6 #? ( *6 D $% '= % 8 6# 9,- % CLH E FG- 6# # +( e.# % *6 D $ K ( 6 # g6 B " # $ % H ' 6 % 8 6# $H j Z 6 f ' 8 6# $ # / 34 $ # 8 6# 6# 9,- % '< # 1N% * / 4 8 6# # B$ 6 =6 %.# % O 6;- e * T@H '6 6 U *! /371 %8 A K #6# H ' 6 $46 B. G( 2.(6 "+&) 1395 "# $%& '( #T@ H '6 e.9 < Q 6 W $ ' 6 - [' *6 D $% (10 mg/lesion) $/ 4 % $ = 64!( 9< Q 6 W [' *6 D $% 10 mg/lesion # % H ' 6 & i6!" #.4? *6 D $% '= * / 4 % $ = 62!(.5 116

4 " # -+,.6 2 $' 4 % [' 375 *6 D $% $m #%'() $' 6# 6% $= $H 6# 7Q $/4 "# O6;- % Primary cutaneous B-cell lymphoma 8 6# 6# $' 4 % 9= 2& 2#'= #6 6;Q 6# CD20+ 7< (PCBCL) p4 # 1N% $ &6;Q a */R $% $ - %.( ) 6# T@H '6 $/4 "# O6;- % 6 CLH */4 % Witzig $/R 6#.#6( # # 8G( 9%6 i6 $' 18 - [' *6 D $% 10 mg/ml # % 6# A 86+@ $46B & "@,- % $% 8 6#.& O6;- $/4 "# $/4 $:K "%W # 1N% # % 2 2 e 9&( D6# 0/1 8 6# 9,- # # B ['H) $% -@'6 :( $%.9&# 2@ $% Q!Gm # 1N% $' 4 e $ 9<Q 6W 8 6# 8 B $% ( '% T@H '6 $/4 "# 8 6# =6 $ 2 # B 73?+& 6# CD20+ */4 8 6# 6# L= 6 $% 2# % $ 9H+& % 8) 6# 1W 8 6#.(15) #6 (b) ; 8'=6@% 2r 86 $=A% $3 8QH.@( (#6W +G- ( 9= 8 ='( % $ 9= -?' CLH.(3-5) # & EFG $ % $ 8 6# &% EFG T B <6?( CLH 9B $ -6 D 6# A $ 8).9= 6 '= 2 G- " B Q $% 73 $ 9= jr */4 8 6# 2 3% ( - 6@% -' 93< % #/' 6 0 % " B (6 A+=H#) - %'() " & /4 ) '= +-6 (TNF-α #%'() 2b ) 8<') [% = " B 6 $/& %- (@'H= $/4 "# B %< $/& % ( 6#6 ( (A6 = += A &% CD20 [(G( $ 9=?( ( #%'() T@H '6 $% 1998?= # 6W I #6 6 B 9= 6 %.(11) 9= $'<Q 6W 2#'= #6 6.- "+& A+m M 7 8 6# 6# 4K?K 6# 6# A ) (NHL 1( $46B A-Y&.(3) # & Non-Hodgkin's lymphoma) "@,- % $% n- AK o= ' #6# 9= ['<% 6# ;.-.(11-13) 9= 8) /4 O6;- 1( $46B A-Y& O6;- References 1. Anandasabapathy N, Pulitzer M, Epstein W, Rosenman K, Latkowski JA. Pseudolymphoma evolving into diffuse large B-cell lymphoma. Dermatol Online J 2008; 14(5): Benchikhi H, Bodemer C, Fraitag S, Wechsler J, Delfau- Larue MH, Gounod N, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999; 40(6 Pt 1): Dadban A, Truchetet F. Cutaneous lymphoid hyperplasia on a preexistent melanocytic nevus. Dermatology 2008; 217(3): Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19(2):

5 " # 5. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2011; 64(2): Guis S, Schiano de Colella JM, Bonnet N, Andrac- Meyer L, Balandraud N, Mattei JP, et al. Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept. Eur J Dermatol 2008; 18(4): Khan AQ, Tolat T, Patil A. Cutaneous lymphoid hyperplasia presenting as bilateral post-auricular swellings: a case report. International Journal of Science and Research 2015; 4(2): Lackey JN, Xia Y, Cho S, Sperling LC. Cutaneous lymphoid hyperplasia: a case report and brief review of the literature. Cutis 2007; 79(6): Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007; 215(Suppl 1): Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-cd20 antibody rituximab. Clin Lymphoma Myeloma Leuk 2011; 11(3): Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001; 144(6): Taylor RB, Fortney JA, Pollack RB, Metcalf JS, Jenrette JM. Radiation therapy for B-cell cutaneous lymphoid hyperplasia. Jpn J Radiol 2010; 28(5): Tomar S, Stoll HL, Grassi MA, Cheney R. Treatment of cutaneous pseudolymphoma with interferon alfa- 2b. J Am Acad Dermatol 2009; 60(1): Valencak J, Weihsengruber F, Rappersberger K, Trautinger F, Chott A, treubel B, et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009; 20(2): Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB, et al. Treatment of benign orbital pseudolymphomas with the monoclonal anti- CD20 antibody rituximab. Mayo Clin Proc 2007; 82(6):

6 Journal of Isfahan Medical School Received: Vol. 34, No. 371, 3 rd Week, April 2016 Accepted: Cutaneous Lymphoid Hyperplasia Treated with Rituximab: Report of 4 Patients Abstract Marzieh Matin 1, Ali Asilian 2, Samaneh Mozafarpoor 1, Elaheh Haftbaradaran 3 Case Series Background: Cutaneous benign lymphoid hyperplasia (CLH) is a B-cell pseudolymphoma of unknown origin and the most involving site is the face. Case Report: This report presents 4 CLH patients treated with rituximab. Conclusion: Rituximab may be useful for resistant or relapsing forms of CLH who failed other forms of therapy. Keywords: Cutaneous lymphoid hyperplasia, Rituximab, Treatment Citation: Matin M, Asilian A, Mozafarpoor S, Haftbaradaran E. Cutaneous Lymphoid Hyperplasia Treated with Rituximab: Report of 4 Patients. J Isfahan Med Sch 2016; 34(371): Resident, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 2- Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 3- General Practitioner, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Corresponding Author: Elaheh Haftbaradaran, elahe_md2003@yahoo.com 119

Σχετικά έγγραφα

A summation formula ramified with hypergeometric function and involving recurrence relation

South Asian Journal of Mathematics 017, Vol. 7 ( 1): 1 4 www.sajm-online.com ISSN 51-151 RESEARCH ARTICLE A summation formula ramified with hypergeometric function and involving recurrence relation Salahuddin